Solar urticaria: An ambispective study in a long-term follow-up cohort with emphasis on therapeutic predictors and outcomes

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Pesqué, David
• dc.contributor.author Ciudad, Andrea
• dc.contributor.author Andrades, Evelyn
• dc.contributor.author Soto, Dulce
• dc.contributor.author Gimeno, Ramón
• dc.contributor.author Pujol Vallverdú, Ramon Maria
• dc.contributor.author Giménez Arnau, Anna Maria
• dc.date.accessioned 2024-09-25T05:57:47Z
• dc.date.available 2024-09-25T05:57:47Z
• dc.date.issued 2024
• dc.description.abstract Solar urticaria is a rare photodermatosis with several unknown pathogenic, clinical and therapeutic aspects. This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management and outcomes, and characterized omalizumab response with the use of the high-affinity immunoglobulin E (IgE) receptor (FcεRI) and the Urticaria Control Test. An observational, unicentric, ambispective study was conducted from 2007 to 2023. Solar urticaria was diagnosed in 41 patients with a median follow-up of 60 months. Thirteen patients were prescribed omalizumab, with a median treatment time of 48 months. A significant decrease in FcεRI baseline levels and subsequent median increase in Urticaria Control Test was evidenced after omalizumab prescription in all patients. Drug survival at 48 months was at 88.9%. Omalizumab stepping-down protocol led to sustained omalizumab discontinuation in only 1 patient. Median basal Urticaria Control Test was lower (p < 0.01) in patients who were prescribed omalizumab and in patients without remission. This study contributes to our knowledge of omalizumab outcomes in real-life clinical practice and highlights the pathogenic importance of IgE-mediated pathways in solar urticaria, where FcεRI emerges as a possible biomarker of omalizumab response.
• dc.format.mimetype application/pdf
• dc.identifier.citation Pesqué D, Ciudad A, Andrades E, Soto D, Gimeno R, Pujol RM, et al. Solar urticaria: An ambispective study in a long-term follow-up cohort with emphasis on therapeutic predictors and outcomes. Acta Derm Venereol. 2024 Jan 8;104:adv25576. DOI: 10.2340/actadv.v104.25576
• dc.identifier.doi http://dx.doi.org/10.2340/actadv.v104.25576
• dc.identifier.issn 0001-5555
• dc.identifier.uri http://hdl.handle.net/10230/61208
• dc.language.iso eng
• dc.publisher Medical Journals Sweden
• dc.relation.ispartof Acta Derm Venereol. 2024 Jan 8;104:adv25576
• dc.rights Published by Medical Journals Sweden, on behalf of the Society for Publication of Acta Dermato-Venereologica. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
• dc.subject.keyword Chronic urticaria
• dc.subject.keyword Inducible urticaria
• dc.subject.keyword Omalizumab
• dc.subject.keyword Predictor
• dc.subject.keyword Solar urticaria
• dc.subject.keyword Treatment
• dc.title Solar urticaria: An ambispective study in a long-term follow-up cohort with emphasis on therapeutic predictors and outcomes
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion